

State of Oklahoma Oklahoma Health Care Authority Xalkori® (Crizotinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
) Start Date (or date of next dose):	
	Billing Provider Inform	ation
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
	Prescriber Informati	ion
Prescriber NPI:	Prescriber NPI: Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
C. MET amplification D. Crizotinib will be Soft Tissue Sarcoma A. Diagnosis of sof B. Anaplastic lympl C. Crizotinib will be Other, please provide		No fibroblastic Tumor (IMT)? Yes No No No
3. Has the member experience If yes, please specify adverse re	dence of progressive disease while o	crizotinib therapy? Yes No
Prescriber Signature:		Date:
_		all information is true and correct to the

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.